Research programme: eye disorder therapeutics - Santen Pharmaceuticals/Singapore Eye Research Institute

Drug Profile

Research programme: eye disorder therapeutics - Santen Pharmaceuticals/Singapore Eye Research Institute

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Santen Pharmaceutical; Singapore Clinical Research Institute
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders

Most Recent Events

  • 02 Mar 2017 Santen Pharmaceutical and Singapore Eye Research Institute expand collaboration to create a Santen-SERI joint laboratory for the development of ophthalmic therapeutics, diagnostics and devices
  • 12 Nov 2014 Preclinical trials in Eye disorders in Japan (unspecified route)
  • 12 Nov 2014 Preclinical trials in Eye disorders in Singapore (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top